Back to News
Market Impact: 0.2
LTZ Doses First Participant in Phase 1/1b Trial of LTZ-232 for mCRC and Other Solid Tumors
Source: Business Wire
Healthcare & Biotech
LTZ dosed the first participant in its Phase 1/1b study of LTZ-232 in patients with metastatic colorectal cancer (mCRC) and other solid tumors. The early-stage clinical milestone provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share